403 related articles for article (PubMed ID: 29566840)
1. Real-World Evidence: Useful in the Real World of US Payer Decision Making? How? When? And What Studies?
Malone DC; Brown M; Hurwitz JT; Peters L; Graff JS
Value Health; 2018 Mar; 21(3):326-333. PubMed ID: 29566840
[TBL] [Abstract][Full Text] [Related]
2. Payer perceptions of the use of real-world evidence in oncology-based decision making.
Brixner D; Biskupiak J; Oderda G; Burgoyne D; Malone DC; Arondekar B; Niyazov A
J Manag Care Spec Pharm; 2021 Aug; 27(8):1096-1105. PubMed ID: 34337998
[No Abstract] [Full Text] [Related]
3. Is Real-World Evidence Used in P&T Monographs and Therapeutic Class Reviews?
Hurwitz JT; Brown M; Graff JS; Peters L; Malone DC
J Manag Care Spec Pharm; 2020 Dec; 26(12):1604-1611. PubMed ID: 33251991
[TBL] [Abstract][Full Text] [Related]
4. Use of Real-World Evidence in US Payer Coverage Decision-Making for Next-Generation Sequencing-Based Tests: Challenges, Opportunities, and Potential Solutions.
Deverka PA; Douglas MP; Phillips KA
Value Health; 2020 May; 23(5):540-550. PubMed ID: 32389218
[TBL] [Abstract][Full Text] [Related]
5. Is Real-World Evidence Used in P&T Monographs and Therapeutic Class Reviews?
Hurwitz JT; Brown M; Graff JS; Peters L; Malone DC
J Manag Care Spec Pharm; 2017 Jun; 23(6):613-620. PubMed ID: 28530524
[TBL] [Abstract][Full Text] [Related]
6. Assessing Payers' Preferences for Real-World Evidence in the United States: A Discrete Choice Experiment.
Saldarriaga EM; Hauber B; Carlson JJ; Barthold D; Veenstra DL; Devine B
Value Health; 2022 Mar; 25(3):443-450. PubMed ID: 35227457
[TBL] [Abstract][Full Text] [Related]
7. Payer Perspectives on Patient-Reported Outcomes in Health Care Decision Making: Oncology Examples.
Brogan AP; DeMuro C; Barrett AM; D'Alessio D; Bal V; Hogue SL
J Manag Care Spec Pharm; 2017 Feb; 23(2):125-134. PubMed ID: 28125369
[TBL] [Abstract][Full Text] [Related]
8. Study types and reliability of Real World Evidence compared with experimental evidence used in Polish reimbursement decision-making processes.
Wilk N; Wierzbicka N; Skrzekowska-Baran I; Moćko P; Tomassy J; Kloc K
Public Health; 2017 Apr; 145():51-58. PubMed ID: 28359391
[TBL] [Abstract][Full Text] [Related]
9. Real-World Evidence in Healthcare Decision Making: Global Trends and Case Studies From Latin America.
Justo N; Espinoza MA; Ratto B; Nicholson M; Rosselli D; Ovcinnikova O; García Martí S; Ferraz MB; Langsam M; Drummond MF
Value Health; 2019 Jun; 22(6):739-749. PubMed ID: 31198192
[TBL] [Abstract][Full Text] [Related]
10. Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing-Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative.
Orsini LS; Berger M; Crown W; Daniel G; Eichler HG; Goettsch W; Graff J; Guerino J; Jonsson P; Lederer NM; Monz B; Mullins CD; Schneeweiss S; Brunt DV; Wang SV; Willke RJ
Value Health; 2020 Sep; 23(9):1128-1136. PubMed ID: 32940229
[TBL] [Abstract][Full Text] [Related]
11. PEER-REVIEWED JOURNAL EDITORS' VIEWS ON REAL-WORLD EVIDENCE.
Oehrlein EM; Graff JS; Perfetto EM; Mullins CD; Dubois RW; Anyanwu C; Onukwugha E
Int J Technol Assess Health Care; 2018 Jan; 34(1):111-119. PubMed ID: 29415784
[TBL] [Abstract][Full Text] [Related]
12. Improving transparency to build trust in real-world secondary data studies for hypothesis testing-Why, what, and how: recommendations and a road map from the real-world evidence transparency initiative.
Orsini LS; Monz B; Mullins CD; Van Brunt D; Daniel G; Eichler HG; Graff J; Guerino J; Berger M; Lederer NM; Jonsson P; Schneeweiss S; Wang SV; Crown W; Goettsch W; Willke RJ
Pharmacoepidemiol Drug Saf; 2020 Nov; 29(11):1504-1513. PubMed ID: 32924243
[TBL] [Abstract][Full Text] [Related]
13. Patient-Community Perspectives on Real-World Evidence: Enhancing Engagement, Understanding, and Trust.
Oehrlein EM; Graff JS; Harris J; Perfetto EM
Patient; 2019 Aug; 12(4):375-381. PubMed ID: 30666526
[TBL] [Abstract][Full Text] [Related]
14. Use of real-world evidence in cancer drug funding decisions in Canada: a qualitative study of stakeholders' perspectives.
Clausen M; Mighton C; Kiflen R; Sebastian A; Dai WF; Mercer RE; Beca JM; Isaranuwatchai W; Chan KKW; Bombard Y
CMAJ Open; 2020; 8(4):E772-E778. PubMed ID: 33234584
[TBL] [Abstract][Full Text] [Related]
15. Use of Real-World Evidence for Regulatory Approval and Coverage of Medical Devices: A Landscape Assessment.
Timbie JW; Kim AY; Concannon TW
Value Health; 2021 Dec; 24(12):1792-1798. PubMed ID: 34838277
[TBL] [Abstract][Full Text] [Related]
16. Payer perceptions on the use of patient-reported outcomes in oncology decision making.
Oderda G; Brixner D; Biskupiak J; Burgoyne D; Arondekar B; Deal LS; Quek RG; Niyazov A
J Manag Care Spec Pharm; 2022 Feb; 28(2):188-195. PubMed ID: 34806908
[No Abstract] [Full Text] [Related]
17. Online tools to synthesize real-world evidence of comparative effectiveness research to enhance formulary decision making.
Chen S; Graff J; Yun S; Beal B; Ta JT; Bansal A; Carlson JJ; Veenstra DL; Basu A; Devine B
J Manag Care Spec Pharm; 2021 Jan; 27(1):95-104. PubMed ID: 33377442
[TBL] [Abstract][Full Text] [Related]
18. Real-world evidence for coverage decisions: opportunities and challenges.
Hampson G; Towse A; Dreitlein WB; Henshall C; Pearson SD
J Comp Eff Res; 2018 Dec; 7(12):1133-1143. PubMed ID: 30411972
[TBL] [Abstract][Full Text] [Related]
19. RWE Framework: An Interactive Visual Tool to Support a Real-World Evidence Study Design.
Xia AD; Schaefer CP; Szende A; Jahn E; Hirst MJ
Drugs Real World Outcomes; 2019 Dec; 6(4):193-203. PubMed ID: 31741199
[TBL] [Abstract][Full Text] [Related]
20. Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration.
Chan K; Nam S; Evans B; de Oliveira C; Chambers A; Gavura S; Hoch J; Mercer RE; Dai WF; Beca J; Tadrous M; Isaranuwatchai W
BMJ Open; 2020 Jan; 10(1):e032884. PubMed ID: 31915169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
